JMKX001899 + pemetrexed + carboplatin

JMKX001899 + pemetrexed + carboplatin is a combination regimen under investigation for advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation. **JMKX001899** is a selective small molecule inhibitor of the KRAS G12C protein, an oncogenic driver mutation prevalent in subsets of NSCLC; it works by irreversibly binding and inhibiting mutant KRAS G12C, thereby blocking downstream oncogenic signaling and cell proliferation. **Pemetrexed** (also known as Alimta) is an antimetabolite chemotherapy that inhibits folate-dependent enzymes involved in DNA synthesis. **Carboplatin** is a platinum-based chemotherapy drug causing DNA crosslinking and apoptosis of rapidly dividing cells. The combination is being studied in phase 1b trials, particularly to assess safety and efficacy in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations[1][3][4][6].

Other names

JMKX001899 + pemetrexed + carboplatin